Navigation Links
Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study
Date:8/26/2009

OSAKA, Japan, and FORT LEE, N.J., Aug. 26 /PRNewswire/ -- Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.

"We are pleased with the results of this study as these data reinforce our belief that lurasidone will be an important treatment option for patients with schizophrenia," said Masayo Tada, president and chief executive officer, Dainippon Sumitomo Pharma Co., Ltd. "We plan to submit our NDA filing package for lurasidone to the U.S. FDA in early 2010."

PEARL 2 (Program to Evaluate the Antipsychotic Response to Lurasidone) is part of an extensive worldwide phase 3 clinical development program, involving more than 2,000 patients, intended to evaluate the safety and efficacy of lurasidone for the treatment of schizophrenia. The PEARL 2 study was a double-blind, fixed-dose, placebo-controlled clinical trial involving 478 inpatients with acute schizophrenia that were randomized to receive either lurasidone 40 or 120 mg/day, olanzapine 15 mg/day or placebo for six weeks. The active comparator, olanzapine, was used for purposes of establishing assay sensitivity.

Lurasidone 40 and 120 mg, taken once-daily, demonstrated significantly greater improvement versus placebo on the primary efficacy measure, the Positive and Negative Syndrome Scale (PANSS) total score, at study endpoint. PANSS score changes from baseline for lurasidone 40 and 120 mg/day versus placebo were -25.7 and -23.6 vs. -16.0, respectively,
'/>"/>

SOURCE Dainippon Sumitomo Pharma Co., Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
2. Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
5. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
6. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
7. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
8. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
9. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
10. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
11. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... May 1, 2015  CytRx Corporation (CYTR), a ... today reported financial results for the three months ... of recent accomplishments and upcoming milestones for its ... milestones in the early months of 2015, including ... trial of aldoxorubicin in patients with soft tissue ...
(Date:5/1/2015)... Pharmacyclics, Inc. (the "Company") (NASDAQ: PCYC ) today ... 2015, as well as general business updates. Due to ... be held. Key Highlights , Total ... to $206 million from $119 million for the quarter ... (ibrutinib) net product revenue of $247 million was ...
(Date:5/1/2015)... , May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... Timothy E. Morris , chief financial officer  will ... the events are as follows: Mizuho Third ... Location:  The Omni Berkshire Place, New York ...
Breaking Medicine Technology:CytRx Reports First Quarter 2015 Financial Results 2CytRx Reports First Quarter 2015 Financial Results 3CytRx Reports First Quarter 2015 Financial Results 4CytRx Reports First Quarter 2015 Financial Results 5CytRx Reports First Quarter 2015 Financial Results 6CytRx Reports First Quarter 2015 Financial Results 7CytRx Reports First Quarter 2015 Financial Results 8CytRx Reports First Quarter 2015 Financial Results 9CytRx Reports First Quarter 2015 Financial Results 10CytRx Reports First Quarter 2015 Financial Results 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 2Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 3Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 4Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 5Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 6Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 7Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 8Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 9Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 10Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 11Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 12Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 13Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 14Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 15Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 16Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 17Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 18Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 19Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 20Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 21Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 22Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 23Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 24Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 25Pharmacyclics Reports First Quarter 2015 Financial Results and Provides Business Updates 26
... Reportlinker.com announces that a new market research ... Growth Hormone Deficiency Global Clinical ... http://www.reportlinker.com/p0567405/Growth-Hormone-Deficiency-Global-Clinical-Trials-Review-Q2-2011.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development Growth Hormone ... Summary ...
... Details of advances in the use of stereotactic body ... high risk operable and inoperable cases were presented at the ... today, including significant improvements in survival of elderly lung cancer ... SBRT treatments. A study into survival rates ...
Cached Medicine Technology:Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 2Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 3Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 4Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 5Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 6Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 7Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 8Growth Hormone Deficiency Global Clinical Trials Review, Q2, 2011 9Significant Rise in Survival Rates for Elderly Lung Cancer Patients Treated Using Radiosurgery in Netherlands Detailed at World Conference for Lung Cancer 2Significant Rise in Survival Rates for Elderly Lung Cancer Patients Treated Using Radiosurgery in Netherlands Detailed at World Conference for Lung Cancer 3Significant Rise in Survival Rates for Elderly Lung Cancer Patients Treated Using Radiosurgery in Netherlands Detailed at World Conference for Lung Cancer 4Significant Rise in Survival Rates for Elderly Lung Cancer Patients Treated Using Radiosurgery in Netherlands Detailed at World Conference for Lung Cancer 5Significant Rise in Survival Rates for Elderly Lung Cancer Patients Treated Using Radiosurgery in Netherlands Detailed at World Conference for Lung Cancer 6
(Date:5/4/2015)... (PRWEB) May 04, 2015 “St. Louis ... the “Gateway to the West,” so it is the ... Veterans Program”, says Dr. Ben Litalien, Chief Development Officer ... Association’s VetFran program and will provide veterans with a ... Zerorez® is proud to have a number of Military ...
(Date:5/3/2015)... Metamora, Michigan (PRWEB) May 03, 2015 Barbara Crone ... worked to enhance the well being of the men, women and ... a hospital, followed by providing care for families in the home. ... an Adult Nurse Practitioner began wondering if I could complete their ... of my own children with my mentor Nurse Midwife, I knew ...
(Date:5/3/2015)... Bubbly Walrus ” was featured on NewsWatch as part of ... and coolest applications on the market for iOS, Android, and ... conducted the app review and shared with viewers how this ... to play on smartphones are the ones that get users ... a video game that just absorbs attention, why not exercise ...
(Date:5/3/2015)... May 03, 2015 NuevaCare announced today ... two upcoming area seminars. The first event will take ... Regional Stroke Conference to be held at The Magnolia ... Wednesday, May 13 during the Dementia Conference to be ... “These seminars offer an excellent opportunity to learn about ...
(Date:5/2/2015)... 2015 As one of only 30 ... Safety and Health Achievement and Recognition Program (SHARP) certification, ... chosen by the Illinois Department of Labor to host ... maintained SHARP certification by the Occupational Safety and Health ... has continued to meet or exceed all of the ...
Breaking Medicine News(10 mins):Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:An Application to Have Fun with Mathematics Was Featured on NewsWatch Television 2Health News:NuevaCare Introduces MnemeTherapy® Approach to Care for Elderly Patients with Alzheimer’s, Stroke and Other Types of Neurodegenerative Conditions 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3
... Inc. told the National Heritage Insurance Co., the contractor that ... to cover its test. ,After this the company’s ... to $12.41 on Nasdaq. The company prepares oncotype DX breast ... taking all the responsibility to cover the medical expenses related ...
... virus has been steadily increasing, with more// than 50 ... in other parts of the territory. // Furthermore, reports of ... past three weeks has prompted reasons for concern among the ... occurred has been one that hit Darwin a decade ago ...
... time from six weeks to five days. This is very useful ... can point the radiation source at the tumor killing the cancer ... therapy over the conventional six-week treatment. They are also in the ... ,But the Canadians are working on a new therapy for breast ...
... Scientist working at the DeCode Genetics Inc (Reykjavik company) was ... the diabetic population in US. ,The Icelandic ... is not known, but is thought to regulate the genes ... in the Icelandic population, as they are a close nit ...
... Pathology, University of Michigan Medical School has reported in ... for producing hypersensitive immune response leading to autoimmune disease. ... the bacteria against which the protein produces an immune ... the immune system to produce an immune response against ...
... the fourth largest reservoir of scientific and research talent ... is poised to emerge as the preferred hub for ... knowledge economy are not restricted to information and communication ... biotech, nanotechnology, missile technology and space. ,India's ...
Cached Medicine News:Health News:Western Australia Witnesses Rise In Ross River Virus Infection 2Health News:Gene Linked To Type 2 Diabetes Identified 2Health News:India set to become the global knowledge hub 2Health News:India set to become the global knowledge hub 3Health News:India set to become the global knowledge hub 4
Insert only, Ethicon medium-large clip size...
Ethicon, medium-large clip size, 10mm, rotatable take apart...
... and IMMULITE 1000 assays are ... IMMULITE and IMMULITE 1000, continuous ... offer simplicity in both design ... be found in a wide ...
... Piccolo is the first compact, broad menu ... testing in any treatment setting. Care givers ... panels with less than one minute of ... comparable in quality to larger, expensive laboratory ...
Medicine Products: